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ORAL QUESTION (0-24/75) 
with debate, pursuant to Rule 47 of the Rules of Procedure 
by Mr LAGORCE on behalf of the Socialist Group 
to the Commission of the European Communities 
Subject: Abuses and fraudulent practices of the major 
pharmaceutical laboratories in Europe 
More and more works and press articles are being published 
denouncing the serious abuses and fraudulent practices of 
the major multinational laboratories in Europe1 .; 
On the one hand these laboratories are putting on the 
market useless and even dangerous products claiming them 
to be innovative and subjecting the consumer to a barrage 
of publicity. On the other hand, they frequently arrange 
among themselves to fix prohibitive prices and take 
advantage of the lack of European legislation to deflect 
the flow of trade between Member States. 
It is estimated that 90% of the medicaments put on the 
market each year are simply old products in a different 
guise which make absolutely no contribution to medical 
science. The pharmaceutical industries thus help to feed 
inflation. The health of the consumer seems at present 
to be the least of their concerns. The problem is 
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complicated by the fact that some of these leading laboratories are 
situated in Switzerland or in the u.s. and the enormous profits 
made are passed thro~gh 'tax havens'. 
Now, it often happens that the national bodies responsible for the 
control of medicaments are unable to discharge their task properly, 
owing to their lack of resources. This is particularly the case in 
a country like France. 
It is for these reasons that, in most of our Member States, there is 
a growing body of opinion in favour of stamping out the abuses 
detected and even calling in some cases for the nationalization of 
the pharmaceutical industries to achieve this aim. 
1. Does the Commission not feel, as we do, that, in view of the 
volume of capital involved and the magnitude of the profits 
made in this sector, the situation on the European market in 
pharmaceutical products demands urgent action on its part? 
2. Does the Commission not consider it necessary and urgent as a 
first step, to apply Articles 85 and 86 of the EEC Treaty in 
the sector of pharmaceutical products? 
3. Does the Commission not consider it also necessary to strengthen 
Community legislation in this area, by means of directives more 
strictly regulating the conditions under which medicaments are 
manufactured, the fixing of their prices, their introduction on 
the market, their presentation, the publicity they enjoy, their 
distribution and rigorous tests to determine not only their 
efficacy but also their non-toxicity? 
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